Philip A. Thompson, M.B., B.S. (Hons)

Peer-Reviewed Articles

1. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson PA, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol 194(1):61-68, 2021. e-Pub 2021. PMID: 33973230.
2. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. PMID: 33792630.
3. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
4. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2020. PMID: 33264443.
5. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
6. Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J 11(3):57, 2021. e-Pub 2021. PMID: 33714981.
7. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
8. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson PA, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):1-13, 2021. e-Pub 2020. PMID: 32392559.
9. Furqan F, Watson G, Samaniego F, Fayad LE, Rashmi Kanagal-Shamanna , Morrison MW, Thompson PA, Steiner RE, Chi L, Dabaja B, Pinnix CC, Neelapu SS, Nastoupil LJ, Strati P. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32650677.
10. Frei M, Aitken SL, Jain N, Thompson P, Wierda W, Kontoyiannis DP, DiPippo AJ. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma 61(10):1-4, 2020. e-Pub 2020. PMID: 32530347.
11. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
12. Thompson P. BTK Inhibitors and Chemoimmunotherapy for CLL. Clin Lymphoma Myeloma Leuk 20 Suppl 1:S22-S24, 2020. PMID: 32862855.
13. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34(6):1588-1598, 2020. e-Pub 2019. PMID: 31862959.
14. Khazal S, Ragoonanan D, Hosing C, Williams L, Medeiros LJ, Mahadeo KM, Thompson PA. Epstein - Barr virus specific cytotoxic T lymphocytes for the treatment of severe epstein-barr virus mucocutaneous ulcer. Br J Haematol 189(2):e33-e36, 2020. e-Pub 2020. PMID: 32150641.
15. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. Blood 135(7):510-513, 2020. e-Pub 2020. PMID: 31895947.
16. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. PMID: 32023374.
17. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2019. PMID: 31553487.
18. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
19. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Undetectable MRD Using Next Generation Sequencing is Associated With Improved PFS After Treatment with FCR for CLL. Blood 134(22):1951-1959, 2019. e-Pub 2019. PMID: 31537528.
20. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. PMID: 31724006.
21. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
22. Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell 36(4):369-384.e13, 2019. e-Pub 2019. PMID: 31543463.
23. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
24. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 125(15):2579-2586, 2019. e-Pub 2019. PMID: 30985931.
25. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
26. Van Roosbroeck K, Bayraktar R, Calin S, Bloehdorn J, Dragomir MP, Okubo K, Bertilaccio MTS, Zupo S, You MJ, Gaidano G, Rossi D, Chen SS, Chiorazzi N, Thompson PA, Ferrajoli A, Bertoni F, Stilgenbauer S, Keating MJ, Calin GA. miRNAs involvement in the pathogenesis of Richter's syndrome. Haematologica 104(5):1004-1015, 2019. e-Pub 2018. PMID: 30409799.
27. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. PMID: 31076409.
28. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
29. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011-1019, 2019. e-Pub 2018. PMID: 30530801.
30. Strati P, Gabutti C, Thompson PA, Kontoyiannis DP, Ferrajoli A. Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. Leuk Lymphoma 60(2):1-3, 2019. e-Pub 2018. PMID: 29911929.
31. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
32. Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249-2259, 2018. e-Pub 2018. PMID: 30254130.
33. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32(10):2278-2281, 2018. e-Pub 2018. PMID: 29479067.
34. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
35. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
36. Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, Topp MS. Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression. Am J Hematol 93(3):371-374, 2018. e-Pub 2017. PMID: 29178361.
37. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2017. PMID: 29047158.
38. Khan M, Siddiqi R, Thompson PA. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. Ann Hematol 97(1):1-15, 2018. e-Pub 2017. PMID: 29063177.
39. Thompson PA, Burger JA. Bruton's tyrosine kinase inhibitors: First and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs 27(1):1-12, 2018. e-Pub 2017. PMID: 29125406.
40. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 180(1):33-40, 2018. e-Pub 2017. PMID: 29164608.
41. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer 141(10):2076-2081, 2017. e-Pub 2017. PMID: 28722170.
42. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 123(12):2268-2273, 2017. e-Pub 2017. PMID: 28171709.
43. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 92(6):E114-E117, 2017. e-Pub 2017. PMID: 28295472.
44. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long term follow up of treatment with ibrutinib and rituximab (IR) in patients with high-risk Chronic Lymphocytic Leukemia (CLL). Clin Cancer Res 23(9):2154-2158, 2017. e-Pub 2016. PMID: 27797975.
45. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
46. Thompson PA, Ravandi F. How I manage patients with hairy cell leukaemia. Br J Haematol 177(4):543-556, 2017. e-Pub 2017. PMID: 28146266.
47. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol 177(4):567-577, 2017. e-Pub 2017. PMID: 28295181.
48. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol 91(11):E478-E479, 2016. e-Pub 2016. PMID: 27468087.
49. Thompson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol 175(3):462-466, 2016. e-Pub 2016. PMID: 27611233.
50. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer 122(16):2505-11, 2016. e-Pub 2016. PMID: 27182988.
51. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma 57(7):1-9, 2016. e-Pub 2015. PMID: 26472485.
52. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 122(4):565-73, 2016. e-Pub 2015. PMID: 26588193.
53. Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127(3):303-9, 2016. e-Pub 2015. PMID: 26492934.
54. Jiang Y, Chen H-C, Su X, Thompson PA, Liu X, Do K-A, Wierda W, Keating MJ, Plunkett W. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2). Blood Cancer Journal 6(e465), 2016. e-Pub 2016.
55. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 39(12):1367-74, 2015. e-Pub 2015. PMID: 26547258.
56. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121(20):3612-21, 2015. e-Pub 2015. PMID: 26193999.
57. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clin Proc 90(10):1440-54, 2015. PMID: 26434969.
58. Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol 90(6):471-7, 2015. e-Pub 2015. PMID: 25683856.
59. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol 33(14):1557-63, 2015. e-Pub 2015. PMID: 25847930.
60. Thompson PA, May D, Choong PF, Tacey M, Liew D, Cole-Sinclair MF. Predicting blood loss and transfusion requirement in patients undergoing surgery for musculoskeletal tumors. Transfusion 54(6):1469-77, 2014. e-Pub 2014. PMID: 24411009.
61. Thompson PA, Lim A, Panek-Hudson Y, Tacey M, Hijazi R, Ng AP, Szer J, Ritchie D, Bajel A. Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 20(6):781-6, 2014. e-Pub 2014. PMID: 24548876.
62. Doo NW, Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K, Burbury K, Wolf M, Joyce T, Harrison SJ. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymphoma 54(7):1465-72, 2013. e-Pub 2012. PMID: 23121086.
63. McKelvie PA, Thompson PA, Tam CS. Peripheral T cell and natural killer (NK) T cell lymphomas: a clinicopathological study from a single Australian centre. Histopathology 61(2):212-23, 2012. e-Pub 2012. PMID: 22716228.
64. Howman R, Thakerer A, Pitman M, Ding N, Thompson PA, Khot A, Harrison SJ. Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy. Leuk Lymphoma 51(12):2299-302, 2010. e-Pub 2010. PMID: 20929329.
65. Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. e-Pub 2016. PMID: 27301277.
66. Li N, Wang SA, Lin P, Jabbour E, Thompson P, Chen Z, Li S, Xu J, You MJ, Bueso-Ramos CE, Medeiros LJ, Yin CC. Relapsed B-acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. Am J Hematol. e-Pub 2019. PMID: 30916805.
67. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson PA, Kantarjian HM, Keating MJ, Burger JA. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. Blood. e-Pub 2021. PMID: 34521099.
68. Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, El Hussein S, Thompson PA, Jain N, Kantarjian HM, Jabbour EJ. Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. e-Pub 2021. PMID: 34464974.
69. Jain N, Thompson PA, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. e-Pub 2021. PMID: 34007049.
70. Jain N, Keating M, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. e-Pub 2021. PMID: 34110383.
71. Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. e-Pub 2021. PMID: 33833386.
72. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. e-Pub 2021. PMID: 33793964.
73. Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. e-Pub 2021. PMID: 33730844.

Invited Articles

1. Thompson PA, Tam CS. Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL. Oncology (Williston Park) 32(6):291-2, 294-6, 2018. PMID: 29940059.
2. Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic endpoint: working toward cure for patients with CLL. Blood 127(3):279-86, 2016. e-Pub 2015. PMID: 26576865.
3. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc 90(10):1440-1454, 2015. PMID: 26434969.
4. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 50 Suppl 2:S55-62, 2015. PMID: 26039209.
5. Thompson PA, Shpall EJ, Keating MJ. Shifting paradigms in the treatment of chronic lymphocytic leukemia. Future Oncol 11(4):641-57, 2015. PMID: 25686119.
6. Thompson PA, Prince HM. Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis. Curr Hematol Malig Rep 8(3):196-210, 2013. PMID: 23765424.
7. Best G, Thompson P, Tam CS. Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. Leuk Lymphoma 53(11):2105-15, 2012. e-Pub 2012. PMID: 22568511.

Editorials

1. Thompson PA. MRD negativity as a surrogate for PFS in CLL?. Blood 131(9):943-944, 2018. PMID: 29496697.
2. Thompson PA, Tam CS. CD38 expression in CLL: a dynamic marker of prognosis. Leuk Lymphoma 55(1):1-2, 2014. PMID: 23540343.
3. Thompson PA, Tam CS, Thursky K, Seymour JF. Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leuk Lymphoma 51(9):1592-5, 2010. PMID: 20807092.

Abstracts

1. Chihara D, Thompson PA, Kantarjian HM, O'Brien SM, Ferrajoli A, Jain N, Burger JA, Estrov Z, Faderl S, Wierda WG, Keating MJ. Chemoimmunotherapy for patients with chronic lymphocytic leukemia: MD Anderson experience beyond FCR300. Blood 128(22):2047, 2016.
2. Aoki E, Jain P, Ferrajoli A, Estrov Z, Keating M, O'Brien SM, Wierda WG, Jain N, Thompson PA, Jabbour E, Pierce S, Hosing C, Kantarjian HM, Ravandi F, Kadia TM. Characteristics, outcomes and treatment of patients with T-cell prolymphocytic leukemia (T-PLL) - single-center experience. Blood 128(22):2997, 2016.
3. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, O'Brien SM, Bose P, Thompson PA, Jain N, Wierda WG, Keating M, Estrov Z. Casein kinase-2 induces constitutive phosphorylation of STAT3 in CLL cells. Blood 128(22):4374, 2016.
4. Strati P, Thompson PA, Keating M, Hinojosa C, Rodriguez D, Wang X, Daver NG, Jain N, Burger JA, Estrov Z, Wierda WG, Kantarjian HM, O'Brien S, Ferrajoli A. A phase II study of the combination of lenalidomide and rituximab in patients with treatment-naive and relapsed chronic lymphocytic leukemia. Blood 128(22):4389, 2016.
5. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian HM, Burger J, O'Brien SM, Wierda WG. Causes of discontinuation and long-term outcomes of patients with CLL after discontinuing ibrutinib. Blood 128(22):4390, 2016.
6. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for CLL: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Presented at the IWCLL Young Investigators Meeting, Sydney, Australia (oral presentation), 2015.
7. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Champlin R, Shpall EJ, Hosing CM. Complex karyotype in chronic lymphocytic leukemia is associated with a high relapse rate post-allogeneic stem cell transplant but durable complete remissions are achieved by immunomanipulation. Presented at the IWCLL, Sydney, Australia (poster presentation), 2015.
8. Thompson PA, Keating MJ, Hinojosa C, Smith S, Jain N, Burger J, Estrov Z, O'Brien SM, Wierda WG, Kantarjian HM, Ferrajoli A. Lenalidomide and rituximab in combination as first-line treatment of CLL: initial results of a phase II study. Presented at the IWCLL, Sydney, Australia (poster presentation), 2015.
9. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Rondon G, Alousi A, Ciurea S, Champlin RE, Ashish Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Results of allogeneic double umbilical cord blood transplantation for relapsed and refractory Hodgkin's lymphoma. Biology of Blood and Marrow Transplant 21(2):S48, 2015.
10. Shaim H, Estrov Z, Sekine T, Kondo K, Ruvolo PP, Thompson P, Sarvaria A, Muftuoglu M, Imahashi N, Liu E, Sobieski C, Wierda W, Keating MJ, Shah N, Hosing CM, Alsuliman A, Basar R, Ferrajoli A, Shpall EJ, Rezvani K. The CXCR4/STAT3/IL-10 pathway controls the immunoregulatory function of chronic lymphocytic leukemia (CLL) and can be modulated by lenalidomide. Blood 126(23):1709, 2015.
11. Kondo K, Burger JA, Keating M, Tran J, Muftuoglu M, Daher M, Shaim H, Thompson P, Imahashi N, Alsuliman A, Wierda W, Liu E, Shpall EJ, Rezvani K. Ibrutinib can modulate the T cell response in chronic lymphocytic leukemia by reducing PD1/PDL1 interactions. Blood 126(23):#1737, 2015.
12. Jain P, Keating MJ, Cleeland C, Renner S, Xuelin H, Gonzalez GN, Harris DM, Wierda W, DiNardo C, Pemmaraju N, Jain N, Thompson P, Ferrajoli A, Burger JA, Kantarjian HM, Verstovsek S, Estrov Z. Ruxolitinib reduces cytokine/chemokine levels and improves fatigue and chronic lymphocytic leukemia (CLL)-related symptoms in CLL patients not requiring systemic therapy. Blood 126(23):2943, 2015.
13. Rozovski U, Harris DM, Li P, Liu Z, Ferrajoli A, Burger JA, Thompson P, Jain N, Wierda W, Keating M, Estrov Z. Stimulation of the B-cell receptor (BCR) induces successive activation of STAT3 and nuclear factor-Kappa-B in CLL cells. Blood 126(23):4125, 2015.
14. Rozovski U, Harris DM, Li P, Liu Z, Ferrajoli A, Burger JA, Thompson P, Jain N, Wierda W, Keating M, Estrov Z. P300 acetylates STAT3 and increases its constitutive transcriptional activity in CLL cells. Blood 126(23):4143, 2015.
15. Farroni JS, Thompson PA, Cortes JE, Gallagher CM. The ethical landscape of patients with leukemia: common issues and best practices. J Clin Oncol 33(15):e18085, 2015.
16. Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Estrov Z, et al.. Beta-2 microglobulin is a dynamic marker of prognosis during treatment with FCR or ibrutinib-based regimens. Haematologica 99((s1)):57 (Poster presentation), 2014.
17. Thompson PA, Ferrajoli A, O'Brien SM, Wierda WG, Keating M, Burger JA. Trisomy 12 is associated with a distinct pattern of lymphocytosis during treatment with ibrutinib, which does not affect response depth or duration. Haematologica 99((s1)):316-317 (poster presentation), 2014.
18. Thompson PA, Rosovski U, Keating MJ, Wierda WG, Falchi L, O'Brien SM, Ferrajoli A. The addition of CD20 monoclonal antibody to lenalidomide improves response rate, TTF and survival in relapsed and refractory CLL. Haematologica 99((s1)):250-251 (Oral presentation), 2014.
19. Thompson PA, Wierda WG, Ferrajoli A, Smith SC, O'Brien SM, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype, rather than del[17p] is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens. Blood 124:22, 2014.
20. Thompson PA, Keating MJ, Hinojosa C, Smith SC, Daver N, Jain N, Burger JA, Estrov Z, O'Brien SM, Wierda WG, Kantarjian HM, Ferrajoli A. Lenalidomide and rituximab in combination as initial treatment of chronic lymphocytic leukemia: initial results of a phase II study. Blood 124:1988 (Poster presentation), 2014.
21. Badar T, Thompson PA, George B, Daver N, Borthakur G, Cortes JE, Konopleva M, Kadia TM, Bohannan Z, Pierce S, Jabbour E, Ravandi F, Kantarjian HM, Patel KP, Luthra R, Sukholutsky V, Garcia-Manero G. Temporal acquisition of FLT3-ITD or RAS mutation at transformation to AML from MDS: clinical implications. Blood 124:4631 (Poster presentation), 2014.
22. Randhawa JK, Kantarjian HM, Borthakur G, Thompson PA, Konopleva M, Daver N, Pemmaraju N, Jabbour E, Kadia TM, Estrov Z, Ramachandran A, Paradela J, Andreef M, Levis M, Ravandi F, Cotes JE. Results of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (pts) with activating FLT3 mutations. Blood 124:1927 (Oral presentation), 2014.
23. Bajel AR, Curley C, Lim ABM, Handunnetti S, Getta B, Thompson PA, Wright MPF, Greenwood M, Hertzberg M, Curtis DJ, Szer J, Kennedy GA, Ritchie D. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia - a multicentre Australian experience: prognostic factors for survival and relapse. Blood 124:1927 (Poster presentation), 2014.
24. Thompson PA, Lim A, Tacey M, Hijazi R, Ng AP, Szer J, et al.. Screening with spirometry is a useful predictor of later development of non-infectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Presented at the Haematology Society of Australia and New Zealand Conference, Gold Coast, Australia:(Oral presentation), 2013.
25. Thompson PA, Lim A, Tacey M, Hijazi R, Ng AP, Szer J, et al.. Screening with spirometry is a useful predictor of later development of non-infectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Blood 122:4603, Abstract 722 (poster presentation), 2013.
26. Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K, Burbury K, Wolf M, Peinert S, Joyce T, Harrison SJ. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Presented at 2009 HAA annual scientific meeting, 2009.

Book Chapters

1. Thompson PA, Rezvani K, Kebriaei P. Cellular therapy in allogeneic hematopoietic cell transplantation. In: MD Anderson Manual of Medical Oncology. McGraw-Hill, 2015.

Letters to the Editor

1. Thompson PA, Ferrajoli A, O'Brien S, Wierda WG, Keating MJ, Burger JA. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 170: 125-8, 2015.
2. Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K, Burbury K, Wolf M, Peinert S, Joyce T, Harrison SJ. Bortezomib added to high dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant 46: 764-65, 2011.
3. Thompson PA, Lade S, Webster H, Ryan G, Prince HM. Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity. Haematologica 95: 1977-9, 2010.
4. Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli A. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol.